{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:30:58Z","timestamp":1785256258687,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU-TB 02.716"],"award-info":[{"award-number":["TTU-TB 02.716"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lanepe.2026.101676","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:07:41Z","timestamp":1775714861000},"page":"101676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Treatment outcomes and long-term relapse-free survival after multidrug-resistant tuberculosis treatment in Latvia: a retrospective national cohort study"],"prefix":"10.1016","volume":"65","author":[{"given":"Sophie Charlotte","family":"Meier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liga","family":"Kuk\u0161a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santa","family":"\u0136au\u0137e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vija","family":"Riekstina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evita","family":"Biraua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-7909","authenticated-orcid":false,"given":"Nityanand","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-4741","authenticated-orcid":false,"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-161X","authenticated-orcid":false,"given":"Thomas Theo","family":"Brehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101676_bib1","series-title":"Global Tuberculosis Report 2025","year":"2025"},{"key":"10.1016\/j.lanepe.2026.101676_bib2","series-title":"Global Tuberculosis Report 2024","author":"Organization WH","year":"2024"},{"key":"10.1016\/j.lanepe.2026.101676_bib3","series-title":"WHO Treatment Guidelines for Drug-Resistant Tuberculosis","year":"2016"},{"key":"10.1016\/j.lanepe.2026.101676_bib4","series-title":"WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment: Drug-Resistant Tuberculosis Treatment","year":"2020"},{"key":"10.1016\/j.lanepe.2026.101676_bib5","series-title":"WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment and Care","year":"2025"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101676_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jinf.2023.06.014","article-title":"Global treatment outcomes of extensively drug-resistant tuberculosis in adults: a systematic review and meta-analysis","volume":"87","author":"Pedersen","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.lanepe.2026.101676_bib7","article-title":"Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study","volume":"56","author":"Kherabi","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101676_bib8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.cmi.2023.02.013","article-title":"Long-term treatment outcomes in patients with multidrug-resistant tuberculosis","volume":"29","author":"Maier","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.lanepe.2026.101676_bib9","series-title":"Tuberculosis Surveillance and Monitoring in Europe 2024 - 2022 Data","year":"2024"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101676_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101676_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001117","article-title":"STrengthening the Reporting of OBservational studies in Epidemiology--Molecular Epidemiology (STROBE-ME): an extension of the STROBE Statement","volume":"8","author":"Gallo","year":"2011","journal-title":"PLoS Med"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101676_bib13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMc1603274","article-title":"Treatment outcomes in multidrug-resistant tuberculosis","volume":"375","author":"G\u00fcnther","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101676_bib14","series-title":"Global Tuberculosis Report 2024","year":"2024"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101676_bib15","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1093\/cid\/ciaa1177","article-title":"Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial","volume":"72","author":"Jeronimo","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101676_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.5588\/ijtldopen.24.0620","article-title":"15-year trends in efficacy and effectiveness of treatment outcomes in drug-resistant pulmonary TB","volume":"2","author":"Nasiri","year":"2025","journal-title":"IJTLD Open"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101676_bib18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101676_bib19","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101676_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang'wa","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101676_bib21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101676_bib22","article-title":"BEAT tuberculosis: a randomized controlled trial of a 6-month strategy for rifampicin-resistant tuberculosis","author":"Conradie","year":"2025","journal-title":"medRxiv"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101676_bib23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2213-2600(25)00194-8","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial","volume":"13","author":"Guglielmetti","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101676_bib24","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/cid\/ciaf035","article-title":"The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-Based regimens for rifampicin-resistant tuberculosis in non-trial settings-A prospective cohort study in Belarus and Uzbekistan","volume":"81","author":"Sinha","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101676_bib25","article-title":"Safety and effectiveness of BPaL-Based regimens to treat multidrug-resistant TB: first experience of an Italian tuberculosis referral hospital","volume":"14","author":"Gualano","year":"2024","journal-title":"Antibiotics (Basel)"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101676_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0310773","article-title":"Introducing BPaL: experiences from countries supported under the LIFT-TB project","volume":"19","author":"Wares","year":"2024","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101676_bib27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/ciaf214","article-title":"Effectiveness of the bedaquiline, pretomanid, and linezolid regimen, with or without moxifloxacin, for drug-resistant tuberculosis in Ukraine under programmatic conditions","volume":"81","author":"Dahl","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101676_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106509","article-title":"Long term outcomes in drug resistant tuberculosis with Bedaquiline, Pretomanid and varying doses of Linezolid","volume":"91","author":"Daniel","year":"2025","journal-title":"J Infect"},{"key":"10.1016\/j.lanepe.2026.101676_bib29","article-title":"Effectiveness and safety of the BPaL regimen in the Philippines","volume":"41","author":"Flores","year":"2025","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.lanepe.2026.101676_bib30","article-title":"The use of BPaL containing regimen in the MDR\/PreXDR TB treatments in Thailand","volume":"34","author":"Sangsayunh","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101676_bib31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1164\/rccm.201710-2141OC","article-title":"Clinical management of multidrug-resistant tuberculosis in 16 European countries","volume":"198","author":"G\u00fcnther","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101676_bib32","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1473-3099(24)00228-7","article-title":"Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study","volume":"24","author":"Korotych","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanepe.2026.101676_bib33","series-title":"Meeting Report of the WHO Expert Consultation on the Definition of Extensively Drug-Resistant Tuberculosis","first-page":"27","year":"2020"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101676_bib34","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1473-3099(24)00263-9","article-title":"Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"24","author":"Schwab","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101676_bib36","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S1473-3099(22)00875-1","article-title":"Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet\/RESIST-TB consensus statement","volume":"23","author":"Dom\u00ednguez","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101676_bib37","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00621-2021","article-title":"Emergence of bedaquiline resistance in a high tuberculosis burden country","volume":"59","author":"Chesov","year":"2022","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101676_bib38","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3201\/eid3003.240134","article-title":"Bedaquiline resistance after effective treatment of multidrug-resistant tuberculosis, Namibia","volume":"30","author":"G\u00fcnther","year":"2024","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101676_bib39","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study","volume":"4","author":"Derendinger","year":"2023","journal-title":"Lancet Microbe"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101676_bib40","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3201\/eid3103.241675","article-title":"Fluoroquinolone resistance in drug-resistant tuberculosis, Kharkiv, Ukraine, 2019-2023","volume":"31","author":"Konstantynovska","year":"2025","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101676_bib41","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12890-021-01597-1","article-title":"Multidisciplinary management of difficult-to-treat drug resistant tuberculosis: a review of cases presented to the national consilium in Uganda","volume":"21","author":"Baluku","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.lanepe.2026.101676_bib42","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.ijid.2019.01.040","article-title":"Challenging MDR-TB clinical problems\u2013the case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs","volume":"80s","author":"Tiberi","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101676_bib43","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.5588\/ijtld.18.0779","article-title":"Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium","volume":"23","author":"Guglielmetti","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101676_bib44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.rppnen.2017.10.005","article-title":"Team approach to manage difficult-to-treat TB cases: experiences in Europe and beyond","volume":"24","author":"D'Ambrosio","year":"2018","journal-title":"Pulmonology"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226000888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226000888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:17:36Z","timestamp":1780388256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226000888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":41,"alternative-id":["S2666776226000888"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101676","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment outcomes and long-term relapse-free survival after multidrug-resistant tuberculosis treatment in Latvia: a retrospective national cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101676"}}